Innovotech Inc. Receives Support to Develop Antimicrobial Testing Services and Product Enhancements

(TheNewswire)

Edmonton, Alberta – May 13, 2026 -TheNewswire – Innovotech Inc. (TSX VentureExchange: IOT; OTCQB: IOTCF) (“Innovotech” orthe “Company”) reports that its subsidiary Innovotech LabsCorporation is receiving advisory services and research anddevelopment funding of up to $234,000 CAD from the National ResearchCouncil of Canada Industrial Research Assistance Program (NRC IRAP) tosupport the development of new antimicrobial testing services for usewith medical devices such as catheters, implants, and wound dressings.

The new testing methods align with changes in international regulatorystandards and medical device manufacturers’ needs in the areas ofproliferation, biofilm formation, and translocation of microorganisms.This work builds on foundational development started last year andadvances it into more robust, fit-for-purpose testing. As customerprograms expand, manufacturers are requesting more advanced testingthat better reflects real-world use and provides clearerdecision-making data. Strengthening these capabilities will expand theCompany service offerings, support regulatory readiness, and helpcustomers demonstrate device safety and performance more effectively.

“This NRC IRAP support will help us to deepen our technical bench,problem solve for our customers and deliver solutions that reduceinfections and complications for better health outcomes,” said CraigMilne, CEO. “It also positions us to meet rising client demand withhigher-complexity testing and stronger technical support as standardsand expectations continue to evolve.”

About Innovotech

Innovotech Inc. is a leading life sciences services andtechnology company specializing in contract research, analytical, andmicrobial testing within regulated healthcare markets. The Company isa recognized leader in biofilm science and antimicrobial testing andprovides advanced laboratory services supporting medical device,pharmaceutical, and industrial product development. Innovotechcombines deep scientific expertise with proprietary methodologies andproducts, including its widely used MBEC Assay® platform forhigh?throughput antimicrobial and antibiotictesting. Operating through ISO?certified andGMP?accredited laboratories, Innovotechsupports clients across multiple sectors and geographies, deliveringreliable, decision?enabling data aligned withregulatory expectations such as those of the U.S. Food and DrugAdministration and Health Canada. Learn more at https://www.innovotech.ca.

Craig Milne, CEO    Innovotech Inc.

+1-604-239-1819 craig.milne@innovotech.ca

This document may containforward-looking statements that are predictive in nature and subjectto risks and uncertainties that cannot be predicted or quantified;consequently, actual results may differ materially from past resultsand those expressed or implied by any forward-looking statements.Factors that could cause or contribute to such risks or uncertaintiesinclude, but are not limited to: the regulatory environment includingthe difficulty of predicting regulatory outcomes; changes in the valueof the Canadian dollar; the Company’s reliance on a small number ofcustomers including government organizations; fluctuations inoperating results; government policies or actions; progress and costof clinical trials; reliance on key strategic relationships;uncertainty related to intellectual property protection and potentialcosts associated with its defense; the Company’s exposure tolawsuits and other matters beyond the control of management. Shouldknown or unknown risks or uncertainties materialize, or shouldmanagement’s assumptions prove inaccurate, actual results could varymaterially from those anticipated. The Company undertakes noobligation to publicly make or update any forward- looking statements,except as required by applicable law.

Neither the TSX Venture Exchange norits Regulation Services Provider (as that term is defined in thepolicies of the TSX Venture Exchange) accepts responsibility for theadequacy or accuracy of this release.

###

Copyright (c) 2026 TheNewswire - All rights reserved.